Visual acuity and contrast sensitivity are two important factors affecting vision-related quality of life in advanced age-related macular degeneration

PLoS One. 2018 May 10;13(5):e0196481. doi: 10.1371/journal.pone.0196481. eCollection 2018.

Abstract

Purpose: Vision loss from age-related macular degeneration (AMD) has a profound effect on vision-related quality of life (VRQoL). The pupose of this study is to identify clinical factors associated with VRQoL using the Rasch- calibrated NEI VFQ-25 scales in bilateral advanced AMD patients.

Methods: We retrospectively reviewed 47 patients (mean age 83.2 years) with bilateral advanced AMD. Clinical assessment included age, gender, type of AMD, high contrast visual acuity (VA), history of medical conditions, contrast sensitivity (CS), central visual field loss, report of Charles Bonnet Syndrome, current treatment for AMD and Rasch-calibrated NEI VFQ-25 visual function and socioemotional function scales. The NEI VFQ visual function scale includes items of general vision, peripheral vision, distance vision and near vision-related activity while the socioemotional function scale includes items of vision related-social functioning, role difficulties, dependency, and mental health. Multiple regression analysis (structural regression model) was performed using fixed item parameters obtained from the one-parameter item response theory model.

Results: Multivariate analysis showed that high contrast VA and CS were two factors influencing VRQoL visual function scale (β = -0.25, 95% CI-0.37 to -0.12, p<0.001 and β = 0.35, 95% CI 0.25 to 0.46, p<0.001) and socioemontional functioning scale (β = -0.2, 95% CI -0.37 to -0.03, p = 0.023, and β = 0.3, 95% CI 0.18 to 0.43, p = 0.001). Central visual field loss was not assoicated with either VRQoL visual or socioemontional functioning scale (β = -0.08, 95% CI-0.28 to 0.12,p = 0.44 and β = -0.09, 95% CI -0.03 to 0.16, p = 0.50, respectively).

Conclusion: In patients with vision impairment secondary to bilateral advanced AMD, high contrast VA and CS are two important factors affecting VRQoL.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Contrast Sensitivity / physiology*
  • Female
  • Humans
  • Macular Degeneration / metabolism
  • Macular Degeneration / physiopathology*
  • Male
  • Multivariate Analysis
  • Quality of Life / psychology
  • Retrospective Studies
  • Surveys and Questionnaires
  • Vision, Ocular / physiology
  • Visual Acuity / physiology*

Grants and funding

MR, SA, HS and MJ have nothing to disclose. JWM reports personal fees from Amgen, Inc., personal fees from KalVista Pharmaceuticals, Ltd., non-financial support from Maculogix, Inc., personal fees from Biogen Idec, Inc., personal fees from Alcon Research Council, grants from Lowy Medical Research Institute, Ltd., outside the submitted work; In addition, Dr. Miller has a patent Mass. Eye and Ear/Valeant Pharmaceuticals with royalties paid to Mass. Eye and Ear, and a patent ONL Therapeutics, LLC with royalties paid to ONL Therapeutics, LLC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.